Amyloid-Beta (Aβ) Production/Clearance Balance and Aβ Neurotoxicity in Alzheimer’s Disease: From Mechanisms to Therapy
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Cellular Biochemistry".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 1693
Special Issue Editors
2. O-Force Co., Ltd., Located at 3454 Irino Kuroshio-cho, Hata-gun, Kochi 789-1931, Japan
Interests: Alzheimer's disease; amyloid-beta (Aβ); high-density lipoprotein; oxidative stress
Special Issues, Collections and Topics in MDPI journals
Interests: Alzheimer's disease; amyloid-beta (Aβ); neurodegenerative diseases; bioactive peptides
Special Issue Information
Dear Colleagues,
Alzheimer's disease (AD) is the most common neurodegenerative disease. Pathological proteins of AD mainly contain Aβ and tau. Their accumulation will lead to neuron damage by a series of pathways. Accumulating evidence indicates that the imbalance of Aβ production and Aβ clearance in the brain of AD patients leads to Aβ deposition and neurotoxic Aβ oligomer formation. Thus, to develop efficient strategies to slow down or halt AD, it is pivotal to understand the production and clearance mechanism of Aβ. Extracellular Aβ deposits are cleared from the brain by various Aβ clearance pathways.
The current understanding of Aβ metabolism is still insufficient, which is why all the pharmacologic agents targeting Aβ fail in clinical trials. However, several treatment strategies have been recently proposed. For example, anti-Aβ monoclonal antibodies have been developed successively and conducted in clinical trials based on the theory that the imbalance between Aβ production and clearance contributes to AD occurrence and progression. Further, our group has shown that some small peptides promote Aβ degradation and clearance (Biomolecules. 2022 Nov 27;12(12):1766). In this Special Issue, we will introduce the production and clearance mechanisms of Aβ and summarize targeted drug therapies for AD in relation to this mechanism.
We invite investigators to submit original research and review articles exploring the accumulation and clearance of Aβ in AD. Potential topics include, but are not limited to, the following:
1) Aβ production and assembly.
2) Aβ/oxidative stress-induced neurotoxicity.
3) Clearance mechanisms of Aβ: ubiquitin-proteasome system, autophagy–lysosome system, Aβ-degrading enzymes, microglial phagocytosis, Aβ clearance through blood–brain barrier, glymphatic system, and meningeal lymphatic clearance.
4) Prevention of Aβ accumulation based on the theory that the imbalance between Aβ production/clearance contributes to AD occurrence.
We look forward to your contribution.
Prof. Dr. Fumiaki Ito
Prof. Dr. Toshifumi Akizawa
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Alzheimer's disease
- amyloid-beta (Aβ)
- neurotoxicity of Aβ
- Aβ phagocytosis
- Aβ clearance
- autophagy-lysosome system
- anti-Aβ monoclonal antibodies
- catalytides
